Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

President Trump announces a deal with Novo Nordisk and Eli Lilly to lower the cost of their blockbuster GLP-1 drugs, ...

The drugmaker said it would launch late-stage trials of the drug after participants lost as much as 20% of their body weight.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

Eli Lilly and Novo Nordisk agree to expand access and cut prices for Zepbound and Wegovy • Medicare to begin covering obesity ...

AstraZeneca beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and ...

(Reuters) -Shares of obesity drugmakers Eli Lilly and Novo Nordisk rose early on Thursday in anticipation of a White House ...

Get the latest analysis on Heron Therapeutics (HRTX): current challenges, future outlook, and key growth factors. Click here ...